Related Experiment Video
Updated: Jan 31, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
CP-31398 restored the functional condensates of R175H p53 by stabilizing the zinc-binding domain and 251-258 segment
Yang Liu1, Yuan Liu1, Chang Xu1
1School of Biology and Biological Engineering, South China University of Technology, Guangzhou, Guangdong Province 510006, PR China.
Abstract:
Tumor suppressor p53 formed the droplets with the solidification tendency. Mutations in p53 could accelerate the aggregation of droplets, resulting in p53 to lose the function and/or to gain the oncogenic activity. In this study, the effects of CP-31398 on the phase behaviors of p53 mutants were explored. The results revealed that CP-31398 could inhibit the pathological aggregation of R175H p53, restored the interaction between R175H p53 and specific DNA, and promoted the formation of functional droplets. For R248W p53, CP-31398 could regulate the phase behavior but not restore the formation of functional condensates. Molecular dynamics simulations showed that CP-31398 enhanced the structural stability of R175H p53 by stabilizing the zinc-binding domain and 251-258 segment. These findings provided new insights into the molecular basis that CP-31398 restored the liquid-liquid phase separation of p53 mutant, and could offer the novel therapeutic strategy for cancers with p53 mutant.
Insights
The drug CP-31398 can prevent the pathological aggregation of mutant tumor suppressor p53 (protein 53) by restoring its function. This may offer a new cancer therapy strategy for p53 mutations.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Tumor suppressor p53 (protein 53) can form liquid droplets, but mutations can lead to pathological aggregation, causing loss of function or oncogenic activity.
- Understanding the phase behavior of mutant p53 is crucial for developing targeted cancer therapies.
Purpose of the Study:
- To investigate the effects of CP-31398 on the phase behavior of p53 mutants.
- To explore CP-31398 as a potential therapeutic strategy for cancers with p53 mutations.
Main Methods:
- Studied the effects of CP-31398 on R175H and R248W p53 mutants.
- Utilized molecular dynamics simulations to analyze structural stability.
- Assessed the restoration of p53-DNA interactions and functional droplet formation.
Main Results:
- CP-31398 inhibited pathological aggregation of R175H p53, restored its DNA binding, and promoted functional droplet formation.
- CP-31398 regulated R248W p53 phase behavior but did not restore functional condensate formation.
- Molecular dynamics simulations revealed CP-31398 stabilized the zinc-binding domain and 251-258 segment of R175H p53.
Conclusions:
- CP-31398 can restore liquid-liquid phase separation and function in specific p53 mutants (e.g., R175H).
- The drug's mechanism involves enhancing structural stability of the mutant p53.
- These findings suggest CP-31398 as a potential therapeutic agent for cancers harboring p53 mutations.
Related Concept Videos
Conservation of Protein Domains Over Different Proteins
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...
Restorative Care
Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Aldol Condensation vs Claisen Condensation
Ligand Binding and Linkage
RNA Stability

